World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 1
Page: 141-155

A REVIEW ON TARGETED DRUG DELIVERY SYSTEMS IN ONCOLOGY

Akshaya G*[1], Kiran Revadihal[2], Arindam Dey[3], Shivani Amireddy[4], Robin Roy[5], Shreyaa Datta[6], Vasudev Purushottam Pai[7], Sanivarapu Radhika[8], Nalajala Akash[9] and R. Roshinee[10]

[1]Pharm D, ganeakshaya007@gmail.com, [2]Pharm D, kiranrevadihal18@gmail.com,
[3]Pharm D, arindamdd18@gmail.com, [4]Pharm D, amireddyshivani@gmail.com
[5]Pharm D, robinroyebenezerppy@gmail.com, [6]Pharm D, dattashreyaa@gmail.com
[7]Pharm D, vasudevpai995@gmail.com, [8]Pharm D, sanivarapuradhika1010@gmail.com
[9]Pharm D, akashchowdaryakash@gmail.com, [10]Pharm D, rroshinee99@gmail.com

Article Received: 23 November 2024* | | *Article Revised: 14 December 2024* | | *Article Accepted: 06 January 2025

***Corresponding Author: Akshaya G.**
Pharm D.
DOI: https://doi.org/10.5281/zenodo.14784473

How to cite this Article: Akshaya G*, Kiran Revadihal, Arindam Dey, Shivani Amireddy, Robin Roy, Shreyaa Datta, Vasudev Purushottam Pai, Sanivarapu Radhika, Nalajala Akash and R. Roshinee (2025). A REVIEW ON TARGETED DRUG DELIVERY SYSTEMS IN ONCOLOGY. World Journal of Pharmaceutical Science and Research, 4(1), 141-155. https://doi.org/10.5281/zenodo.14784473

ABSTRACT

Targeted Drug Delivery Systems are a milestone in cancer therapy that represents a new level attacking strategy to bring treatment more precise and effective. They aim at delivering therapeutic agents directly to sites established in tumor tissue and avoiding the establishment of systemic toxicity and improving efficacy. Key concepts in TDDS are passive targeting, for example, the enhanced permeability and retention (EPR) effect, and active targeting which employs receptor or biomarker on cancer cells for selective drug delivery. TDDS have also been widely used in chemotherapy, immunotherapy, gene therapy, RNA-based therapies as well as on-cytotoxic drugs, increasing its therapeutic index while reducing side effects. TDDS are increasingly also deployed in multiple therapeutic debtor combinations, where multiple therapeutic agents are delivered collectively. Nanomedicine takes a lead in diagnosis and imaging of cancer to early identification and monitoring of tumor progression. Its role is broadening over time in clinical applications; the rapid increase of TDDS clinical applications gives way to possibly personalized cancer treatment with better outcomes for patients. Nevertheless, barriers still need to be broken so that effective penetration into tumors and controlled release of therapeutic agents can happen. The advances and works in progress in TDDS can ensure the futuristic era of cancer therapy.

KEYWORDS: Targeted drug delivery, cancer therapy, chemotherapy, immunotherapy, gene therapy, RNA-based therapies, antibody-drug conjugates, nanomedicine, tumor targeting, combination therapy.

INTRODUCTION

Oncology is that special branch of medicine which deals about the diagnosis, treatment, and management of cancer. Generally, cancer signifies uncontrolled proliferation, and dissemination from its point of origin, of abnormal cells that can invade tissues and organs to cause considerable morbidity and mortality. Advances in cancer research led to the emergence of a medley of therapeutic tools such as surgery, radiation, chemotherapy, and immunotherapy, but need has been felt for yet more effective and less harmful treatments mainly because of the limitations shown by most orthodox therapies.[1,2,3]

Precision medicine is a personalized approach for cancer therapies individualized to the specific patient based on his or her genetic, molecular, and clinical profile. This approach will not only provide a more specific and effective therapy tailored to the individual but also reduce the side effects and enhance outcomes for patients. By targeting specific genetic mutations or alterations defined in the tumor cells, precision medicine gives the clinician an opportunity to select therapies that have a higher chance of success, according to the patient's unique disease.

Traditional cancer treatments like chemotherapy and irradiation generally carry the following risks:

- **Systemic Toxicity**: Chemotherapy and radiation act upon almost all normal tissues in the body and produce side effects such as nausea, fatigue, hair loss, and suppression of the immune system.
- **Low Bioavailability**: Many anticancer agents are poorly soluble or unstable, causing limited absorption and reduced therapeutic outcomes, such as poor solubility or instability.
- **Non-specific Action**: The treatment serves both the cancerous as well as healthy tissues making it more likely to develop toxicity and cause a reduction in efficacy.

These are indeed compelling reasons to look for drug delivery systems that are ever more specific and efficient.[4,5,6]

TARGETED DRUG DELIVERY (TDD)

Targeted Drug Delivery (TDD) is the development of delivery systems which take the drug as directly as possible to the site of disease - tumor - with as little exposure as possible to healthy tissues. This concentration, at the target, is intended to increase the therapeutic effect of the drug and decrease the systemic toxicity. Major areas for TDD include the use of nanoparticles, liposomes, antibodies, and conjugates that specifically bind to either tumor-specific markers or those which are able to permeate tumor tissue more effectively.

Targeted-drug delivery systems are remedy techniques designed to transport drugs to their intended organ or tissue, such that once the organ/tissue to be treated is able to receive the drug, there would be little or no exposure to healthy tissues. This precision works to increase the therapeutic efficacy of the drug while minimizing side effects and improving outcomes in the patient. These systems are engineered drug-microsystems (drug carriers-including nanoparticles, liposomes, and micelles), designed to carry and release drugs specifically at the desired passive or active site.[7,8]

PRINCIPLES OF TARGETED DRUG DELIVERY

There are few major principles on which targeted drug delivery works:

- **Specificity**: The system generally prefers targeting a part of a diseased tissue as opposed to the normal tissues. Such satisfaction is often granted by the drug carrier, which could recognize and attach itself to certain selective molecules or receptors present on the target tissue.
- **Controlled Release**: TDDS permits a time course management of the drug, allowing therapeutic drug levels to exist at the target site possibly reduced in frequency of administration and improved patient compliance.
- **Minimized Side Effects**: TDDS minimizes the exposure of healthy tissues to the drug by targeting directly to the action site usually causing a substantial decrease of adverse effects.
- **Enhanced Bioavailability**: Use of carrier systems for drugs protecting the drug from degradation (e.g., digestive enzymes) and possibly aiding absorption and circulation in the bloodstream increased bioavailability.[9,10]

MECHANISMS OF TARGETED DRUG DELIVERY

Active and passive targeting techniques comprise all mechanisms of targeted drug delivery systems that will accomplish selective accumulation of drugs at the target site.

A. Passive Targeting

Passive targeting, on the contrary, takes advantage of the natural distribution pattern of the carriers in the body, using physical and biological factors in directing the drug to the target site.

- **Enhanced Permeability and Retention (EPR) Effect**
  - The EPR effect is the property of leakage blood vessels provided by the diseased tissue, tumor being the best example. Large particles like nanoparticles or liposomes can get into and stay in the tumor site within those intimate structures. There is highly abnormal vasculature in tumors and very poor lymphatic drainage which leads to trapping of drug carriers at tumor sites.
  - **Example**: The drug-loaded nanoparticles accumulate in tumors through the EPR effect for effective delivery, with a reduced extent of systemic toxicity.
- **Leaky Blood Vessels in Inflammatory Tissues**: A similar mechanism can be used for drug delivery to diseased tissues, which have also been shown to have areas of leaky blood vessels like arthritis-inflamed tissues.[11,12]

B. Active Targeting

Active targeting mechanism refers to the following specific types of biological interactions that would lead the drug towards the target site. This usually achieves by the surface modification of the drug carrier using molecules (e.g., ligands, antibodies, peptides), which bind to receptors or antigens present specifically only on the target tissue or cells.

- **Receptor-Mediated Targeting**
  - This particular mode stipulates the addition of particular types of ligands (like antibodies, small-molecule ligands or peptides) onto a drug carrier as they directly deal with the binding and recognition aspects of those ligands to their specific receptors or antigens, which, by definition, are available in an over-expressed way on the surface of a target cell (for example, cancer cells, infected cells, or endothelium within blood vessels).
  - **Example**: An example would be monoclonal antibodies targeting particular receptors, for example HER2 receptors on breast cancer cells; they deliver the drug more specifically to the cancer cells and reduce its toxicity to normal cells.

- **Antibody-Drug Conjugates (ADCs)**
  - It links a cytotoxic drug directly to an antibody, an antibody that attaches to an antigen on the surface of a tumor cell. When the drug becomes attached to the tumor antigen, it is internalized by the cell and causes the drug to be released inside the tumor cell killing it.
- **Ligand-Receptor Interactions**:
  - This employs small molecules, peptides, or any other ligands binding to cell surface receptors to more specifically direct drugs towards those tissues or cells for increased specificity and efficacy of drug delivery.[13,14]

C. Dual-Targeting Systems

Dual-targeting systems actively integrate both passive strategies and active targeting ones a thousand fold to maximize the accuracy and efficacy of drug delivery.

- **Combination of EPR Effect and Receptor Targeting**
  - It first makes the delivery of a therapeutic using the EPR mechanism and, at the same time, binds ligands specific for the receptor to that drug carrier surface to allow for a more precise delivery into diseased cells.
  - **Example:** A nanoparticle drug delivery system might combine the EPR effect to accumulate in a tumor with specific antibodies against tumor antigens for selective targeting of cancer cells.

COMPONENTS OF TARGETED DRUG DELIVERY SYSTEMS (TDDS)

1. Therapeutic Agent (Drug)

An active pharmaceutical ingredient or therapeutic agent is the major part of TDDS. This can be anything meant for the treatment of the disease, like doxorubicin or paclitaxel, or monoclonal antibodies, or further advanced therapies like nucleic acids in oncology (e.g., siRNA or mRNA). The drug must be having a very high potency, stability throughout the delivery process, and should be user-friendly with a compatible carrier system. Works in a therapeutic manner at cancer cells by inhibiting cell proliferation, inducing apoptosis, or modulating activity of the immune system.

2. Carrier System

The term carrier system generally implies a transport agent for the drug that brings it to the target site while preventing premature degradation and clearance. Among the various types of carriers, liposomes, polymeric nanoparticles micelles, dendrimers, and exosomes are some most common. Each one has their own advantages: for example, liposomes give biocompatibility, while polymeric nanoparticles allow control about the release. The carrier system increases drug solubility, stability, and bioavailability, making it possible to gain access to the desired target by ensuring effective and controlled manner.[15,16,17]

3. Targeting Ligands

Targeting ligands are selected molecules that enable the specificity of the TDDS by their binding on the receptors or antigens that are overexpressed by cancer cells or within the tumor microenvironment. These include monoclonal antibodies (e.g., targeting HER2 or CD20), peptides, small molecules (e.g., folic acid for folate receptors), and aptamers. The ligands enable active targeting, which is dependent on ligand-receptor interaction for directing a drug-carrier complex to the cancer cells. This selective approach has heightened therapeutic efficiency while minimizing off-target effects.

4. Release Mechanism

The releasing mechanism controls the specific site delivery of therapeutic agents. Various stimuli are available for TDDS in triggering release, including the acidic tumor microenvironment, temperature elevation, certain enzymes-the matrix metalloproteinases-and external factors, e.g. by ultrasound or magnetic fields. Release mechanisms target activation of the drugs only at the site, which improves therapeutic outcomes while minimizing systemic toxicity and side effects.

5. Stabilizers and Modifiers

Stabilizers and modifiers can be employed in extending the stability and the time of circulation in TDDS while reducing the immune recognition, like in the case of polyethylene glycol (PEG), which forms a hydrophilic cover inside the nanoparticles; albumin, which enhances a longer time of circulation and improved drug delivery. Such substances prevent the earlier degradation from the opsonizating and clearance by the immune system, hence increasing the efficacy of the system.[18,19,20]

6. Targeting Signals

Targeting signals are guiding the TDDS to the actual site of action. Passive targeting signals exploit the physiological differences such as the EPR effect in tumors, while active targeting signals involve ligands that, by means of specific links, bind with receptors on the surface of cancer cells. So, such targeting signals make sure that the drug-carrier complex is concentrated at the tumor site; thus, they improve therapeutic index and reduce collateral damage to healthy tissues.

7. Imaging Agents

Imaging agents, such as fluorescent dyes, radioactive isotopes, or magnetic nanoparticles, are incorporated into some TDDS to allow both real-time drug delivery and therapeutic response monitoring. THESE enables clinicians to check the biodistribution of the drug and evaluate treatment efficiency and hence offer theranostics: combining therapy and diagnostics towards better personalization and precision of therapeutic interventions in cancer.[21,22]

TYPES OF TARGETED DRUG DELIVERY SYSTEMS (TDDS)

1. Liposomes

Liposomes are vesicles that can be formed from lipid bilayers and are used as drug carriers in oncology. Generally, they have the capability for holding hydrophilic as well as hydrophobic drugs and thereby offer protection against degradation and bioavailability improvement. Surface modifications can be provided: for example, using targeted ligands like antibodies or peptides for selective delivery to tumor cells. Liposomes also take advantage of Enhanced Permeability and Retention (EPR) effect, whereby drugs preferentially accumulate within the tumor as a result of leaky blood vessels in the tumor microenvironment. Some successful liposomal formulations such as Doxil (liposomal doxorubicin) have been rather good in reducing toxicity and enhancing the therapeutic efficacy of chemotherapeutic agents.

2. Nanoparticles (Nanomedicines)

The tiniest nanoparticles are between 1 and 100 nanometers, and are the newest technology under investigation for targeted drug delivery applications in oncology. These particles can be made of lipids, polymers, metals, or organic molecules. They either deliver drugs through passive targeting via the enhanced permeation-and-retention (EPR) effect,

where they accumulate in tumors characterized by leaky vasculature, or through active targeting, where specific ligands (for example, antibodies or peptides) are attached on the surface of the nanoparticles to interact with over-expressed receptors in tumor cells. This technology is often used in delivering chemotherapeutic agents like Abraxane (nanoparticle albumin-bound paclitaxel), which improves the bioavailability of drugs and extends their therapeutic potential.[23,24]

3. Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates are among the very current advanced targeted therapies using monoclonal antibodies, which essentially take over all specificity from chemotherapeutic agents on the novel Antibody-Drug Conjugates (ADCs). There are three components included in ADCs: an antibody targeting a specific tumor-associated antigen, a cytotoxic drug (the payload), and something that links the two. Upon binding of the ADC to the tumor cell-associated antigen, the entire complex is internalized with concurrent release of the drug intracellularly. This means that ADCs enable better drug delivery with less systemic toxicity and improved therapeutic index. The most popular examples of ADCs include Kadycla (ado-trastuzumab emtansine) in the treatment of HER2-positive breast cancer and Adcetris (brentuximab vedotin) within the context of Hodgkin lymphoma, which have both indeed made great strides in treating cancers.

4. Polymeric Nanoparticles

Nanoparticles made of polymers are nanocarriers manufactured from biodegradable and biocompatible polymers. These can be engineered for controlled and prolonged release of the drug, ensuring therapeutic concentrations for a longer duration. Being polymers, the size, surface charge, surface functionalization, and other properties of these nanoparticles can be tailored to increase targeting specificity. These nanoparticles can be functionalized with targeting ligands, such as antibodies or peptides, for specific delivery of drugs into the tumor cells. Moreover, polymeric nanoparticles may respond to types such as pH, temperature, or enzymes that will trigger the release of the encapsulated drug in the tumor environment only. This technology is being researched on different anticancer agents, including paclitaxel and doxorubicin, thus it shows a higher promise in augmenting the efficacy of cancer treatment.[25,26]

5. Dendrimers

Dendrimers are very branched tree-and architecture polymers, holding considerable promise for targeted drug delivery because of their highly defined structure and high surface area. Indeed, the unique structure of dendrimers permits the size, shape, and surface functionality to be controlled very precisely. These properties make dendrimers ideal for encapsulation of drugs or for conjugation of drugs to the surface via chemical linkers. In addition, dendrimers can be functionalized with tumor-specific ligands, such as antibodies or small molecules, which would direct them specifically to a cancer cell. They can also be engineered for the release of the drug in response to changes in the environment, such as different pH conditions or specific enzymes. Dendrimers are versatile, and their delivery of anticancer agents and gene therapies is being explored to make treatment more efficient and localized some in future.

6. Micelles

Micelles are colloidal nanoparticles formed from amphiphilic molecules that self-assemble in aqueous solutions. These nanoparticles typically consist of a hydrophobic core and a hydrophilic shell, which allows them to solubilize hydrophobic drugs that are otherwise poorly soluble in water. Micelles can be engineered to enhance the bioavailability

of poorly soluble anticancer agents, and their size and surface properties can be tailored for optimal drug delivery. Similar to other nanocarriers, micelles can accumulate in tumors through the EPR effect or can be functionalized with specific ligands to enable active targeting of tumor cells. This technology is being investigated for the delivery of chemotherapy agents like paclitaxel and doxorubicin, as well as for gene delivery and cancer imaging.

7. Magnetic Nanoparticles

The magnetic nanoparticles are nanoparticles of magnetic materials like iron oxide that are able to deliver drugs to the tumor site by the guidance of an outside magnetic field. These nanoparticles can be loaded with therapeutic agents and guided to the tumor site using magnetic fields, enabling highly selective drug targeting. Besides their capability of achieving magnetic guidance, magnetic nanoparticle application may also shape future strategies in cancer treatment via hyperthermia, where the nanoparticles are heated using an alternation magnetic field, which will lead to the death of tumor cells. Not only delivery of drugs, but also improving imaging techniques and local improvement of cancer therapy can be achieved by using this technology.

8. Gene Therapy Vectors

Gene therapy is a means of treating or preventing diseases through a direct introduction of genes into cells. In cancer, gene therapy is used for delivering genes that can substitute mutated genes in cancer cells, trigger immune responses, or sensitize cancer cells for their action. The above-mentioned gene delivery techniques are accomplished using viral vectors, such as adenoviruses and lentiviruses, which infect tumor cells and transfer therapeutic genes. Gene delivery can also use non-viral methods, such as nanoparticles or liposomes. These vectors may be engineered to target specific tumor tissues so that therapeutic genes can be delivered at sites where they are really required. The gene therapy promises the largest potential in oncology for such innovative fields as immuno-oncology and cancer vaccination.[27,28]

9. Carbon Nanotubes (CNTs)

Carbon Nanotubes (CNTs) are nano-sized structures in the form of hollow cylinders that are made of walls containing entirely carbon atoms, which exhibit unique mechanical, electrical, and chemical properties favourable for drug delivery. CNTs have a hollow interior for the encapsulation of drugs and can serve as surfaces that allow functionalization with targeting ligands for specific drug delivery to cancer cells. Further, CNTs can also serve to carry genetic material or can be used in conjunction with other therapeutic modalities such as photothermal therapy that generates heat upon exposure to light and destroys cancer cells. Their property of penetrating biological barriers, especially the blood-brain barrier, is also an attractive point for treating cancers that are quite difficult to reach.

10. pH-Sensitive Delivery Systems

A pH-sensitive drug transport carrier utilizes the acidic microenvironment of most tumors created out of the rapid growth and altered metabolic activities of cancer cells. In principle, they are designed to release their payload in response to the low pH of the tumor environment. That drug is usually encapsulated in a polymer or lipid-based carrier that has a structural change triggered by acidic conditions, allowing drug release to occur directly at the tumor site. This process means a reduction in systemic exposure, with decreased side effects. Well understood applications of pH-sensitive delivery systems include the controlled release of products such as doxorubicin and paclitaxel while many are being researched for gene therapy and imaging agents.[29,30]

11. Exosome-Based Delivery

Exosomes are tiny particles that can be defined as naturally found extracellular vesicles secreted from the cells. They are basically recognized as an innovative route that could serve the purpose of delivering drugs in the case of oncological applications. Various biological materials, such as proteins, lipids, and RNAs, can be packaged in exosomes that can then be engineered to deliver drugs toward specific target cells. However, what makes exosomes more fascinating relates to their unique facility of crossing biological barriers such as the blood-brain barrier; thus, they serve well for those types of cancers that are rather difficult to reach by target delivery. Exosomes could be loaded with either chemotherapeutic or nucleic acid molecules; they could also be combined with immunomodulatory ones and then directed towards tumor cells through appropriate ligands on the surface. Exosome-based delivery systems are currently being developed for cancer immunotherapy, as well as targeted drug delivery and cancer diagnostics.

12. Nanostructured Lipid Carriers (NLCs)

NLCs are a new kind of lipid-based nanoparticle derived from liposomes but better than them in many of their disadvantages. An NLC consists of a solid lipid core and a liquid lipid shell that helps provide a structure more stable than liposomes. This combination has led to much higher drug-loading capacities and improvements in drug stability. NLCs can get modified and made specific for cellular targeting such that drug delivery is more specific towards cancers. Also, they are capable of sustaining the control release of drugs and thus are considered one of the bests for cancer therapy. In the same way as small, they are being evaluated for anticancer purposes using a wide range of therapeutic drugs, from chemotherapeutics to biologic ones, and also considering their use as combinations for therapeutic purposes.[31,32]

ADVANTAGES OF TARGETED DRUG DELIVERY SYSTEMS IN ONCOLOGY

1. Improved Selectivity and Efficacy

In situ, an important aspect of TDDS systems is that they have the advantages of specifically targeting cancer cells or particular tumor tissues. Instead, different ligands or antibodies would bind to overexpressed receptors on tumor cells, thus giving no chance for the therapeutic agent to reach the intended area. This change would contribute to very high efficacy of the drug; it would act cancer-specifically and thus involve a stronger treatment response with fewer damages caused to healthy tissues surrounding the tumor.

2. Reduced Systemic Toxicity

Chemoprotective drugs generally inflict damage on both malignant and normal cells. Most noticeable generalized toxicities are nausea, fatigue, and, to some extent, organ damage. However, in terms of reduced systemic toxicity, targeted delivery systems would reduce the normal healthy tissues affected by a drug concentration, which would either be carried into or localized at the tumor targeted area. This approach would further reduce adverse effects in patients and, consequently, would improve the quality of life during treatment, while it might also permit the administration of larger doses without subjecting the normal cells to harm.[33,34]

3. Enhanced Bioavailability

Most chemotherapy medications are ineffective for treating conditions they are meant to treat due to shortcomings such as rapid metabolism or low solubility. Transdermal drug delivery systems (TDDS) can provide drugs with solubility, stability, and absorption by enabling very fine particle size and high surface area interactions with the gastrointestinal

juice. Poorly soluble drugs can be embedded in nanoparticles, liposomes, or micelles and delivered to a tumor site to accomplish all this.

4. Sustained and Controlled Drug Release

TDDS can be designed in such a manner that they provide sustained or controlled drug release over a long duration. Such design will assure that the drug concentration at the tumor site remains constant in therapeutic levels over a prolonged duration, thus ensuring maximum effectiveness of treatment. Controlled administration eliminates the fluctuations in concentration that would otherwise lead to drug resistance and frequent dosing herein enhancing patient convenience and compliance to therapy.

5. Overcoming Drug Resistance

Cancer cells develop resistance to known conventional chemotherapy treatment mechanisms by alteration of the metabolism toward drugs, the efflux pumps, or mutations via drug targets. TDDS somehow overcomes these mechanisms of resistance by direct drug delivery to the target tumor cells at therapeutic concentrations. Moreover, these types of combination therapy applications would be synergetic through TDDS in which multiple drugs or therapeutic agents would be co-delivered, which could overcome or mitigate the resistance pathways during the treatment and thus optimize a therapeutic outcome.[35,36]

6. Tumor Microenvironment Targeting

TDDS can be manipulated for acidic pH, hypoxic, or high enzyme activity environments such as matrix metalloproteinases in order to arrest precise release of the drug at the tumor site and the least chance of systemic side effects. Tumor-specific targeting through such microenvironmental factors allows improving delivery of the drug to reach difficult places within tumors, including those poorly vascularized.

7. Personalized Medicine and Precision Oncology

Therapeutic agents will be delivered in a way more specific to an individual's tumor based on the understood genetic/molecular profile of that cancer with the help of TDDSs, thus opening up the new arena of personalized medicine. This delivery could either be through targeting tumor-specific antigens or through targeting genetic mutations, thus facilitating a more personalized therapeutic approach than that available in the conventional setting. This precision is critical in drug delivery so as to make possible the best outcomes and less unnecessary treatment or toxicity.

8. Minimizing Drug Degradation and Clearance

This carrier system in TDDSs quite often creates a protected environment for a drug from premature degradation or clearance by the immune system. A typical example would be liposomes or nanoparticles, which help to shield an enzyme or immune cell from a drug, hence increasing its half-life in the bloodstream. This improved circulation time for the drug will increase the likelihood that it would be able to reach the tumor site before being removed from the body.

9. Combination Therapy

TDDS can be designed to deliver multiple therapeutic agents at the same time and thereby make it possible to use combination therapies with synergies or the combined effect of drugs. For instance, the use of TDDS to deliver a

chemotherapeutic agent along with an immune modulator or a targeted inhibitor could enhance the effectiveness of the treatment and possibly overcome resistance mechanisms. A more complete regimen can be obtained with less toxicity.[37,38]

Table 1: Applications of TDDS.

Application	Description	Examples
Chemotherapy Enhancement	Improves the selectivity and efficacy of chemotherapy by delivering drugs directly to the tumor site.	Liposomal doxorubicin (Doxil), liposomal daunorubicin (DaunoXome)
Targeted Immunotherapy	Enhances delivery of immune-modulating agents to tumor sites, improving immune response and reducing side effects.	Trastuzumab (HER2-positive breast cancer), pembrolizumab (immune checkpoint inhibitor)
Gene Therapy	Uses TDDS to deliver genetic material that induces tumor cell death or enhances immune responses.	Liposomal or viral vector-mediated gene delivery systems
RNA-based Therapies	Delivers small RNA molecules (siRNA, mRNA) to silence oncogenes or promote therapeutic protein production.	Calaspargase pegol (pegylated enzyme delivery)
Targeted Delivery of Cytotoxic Drugs	Delivers potent cytotoxic agents selectively to cancer cells, minimizing toxicity to normal tissues.	Trastuzumab emtansine (Kadcyla), ADCs (antibody-drug conjugates)
Nanomedicine for Tumor Imaging	Uses nanoparticles for enhanced imaging of tumors, aiding in early detection and monitoring.	Magnetic nanoparticles, quantum dots for MRI/PET/CT imaging
Combination Therapy	Delivers multiple therapeutic agents (e.g., chemotherapy + immunotherapy) via a single carrier for synergistic effects.	Nanoparticles delivering both chemotherapeutic agents and immune checkpoint inhibitors

CHALLENGES IN TARGETED DRUG DELIVERY SYSTEMS (TDDS)

1. Heterogeneity of Tumors

Tumors can have very heterogeneous cancer cells that can have very clear-cut genetic, phenotypic, and molecular characters from each other. That is why they may express target receptors or antigens differently; hence there may be differences in the efficacy for different participants, for that all these factors render some cancer cells non-expressing receptors for which targeted delivery systems are designed to work. Thus, a number of cancer cells fail to be targeted and, therefore, lead to reduced efficacy of the therapeutic interventions. This poses a very big challenge for the delivery of drugs by TC which are supposed to be able to deliver them to the cells of choice-which are those of a heterogeneous tumor.

2. Off-Target Effects and Toxicity

TDDS is designed to specifically address the cancerous cells in the tumor tissue but still shows some percentage of the chance of attaching to normal parts of the body. This shows that they may have attached effects and effects. For instance, some ligands specific for cancer cells may bind to normal cells as well since they have similar receptors; thus, further effects may be elicited. Again, the carriers themselves may incite immune reactions to cause toxicity. So, they constitute the basis for intensive study in minimizing the off-target effects from TDDS.

3. Tumor Microenvironment Barriers

There are several barriers in the tumor microenvironment (TME) that can make it difficult for drugs to reach their target effectively. Most tumors have scant, abnormal vascularization, resulting in erratic blood flow and low oxygen concentration. This results in difficulty for drug delivery systems to reach deep within the tumor. Further, few tumors

have a very dense or fibrous extracellular matrix that stifles the diffusion of nanoparticles or other delivery vehicles. That is largely due to such physical barriers that would hinder TDDS from delivering drugs effectively within the entire tumor.[39,40,41]

4. Drug Resistance Mechanisms

Tumors can still develop resistance against the delivered therapy, even though a targeted delivery is proposed. Cancer cells may develop the ability to downregulate the expression of the target receptor or antigen, and this causes a reduced receptiveness to receptor-mediated targeting. Furthermore, tumors may use alternative routes from receptor targeting to become independent from drug action through the activation of other pathways or upregulation of efflux pumps. The prohibitive resistance mechanisms greatly reduce the effectiveness of TDDS, hence the necessity for designing strategies to avoid or circumvent the resistant mechanism.

5. Limited Penetration of Delivery Systems

TDDS penetration into tumor tissue remains a key obstacle, particularly for solid tumors with dense, poorly permeable stroma. Enhanced Permeability-and-Retention (EPR) effect might allow passive targeting in some cases; however, it is not always present in every tumor: such as interstitial fluid pressure being high or presence of irregular blood vessels rendering a tumor ineffective for accumulation of nanoparticles. Besides, the size and the surface properties of the carrier system determine tumor penetration with larger particles almost butchered from joining the tumor environment.[42,43]

6. Complexity of Formulation and Manufacturing

Designing and manufacturing TDDS with the desired characteristics, such as size, surface charge, stability, and drug release kinetics, is a laborious and difficult proposition. Optimization of carrier systems in terms of drug stability and prevention of premature release would be aimed at attaining the desired targeting specificity. Then again, large-scale production of these systems while observing quality control and reproducibility is another problem. For successful clinical application, the consistency and safety of TDDS formulations are paramount.

7. Immunogenicity and Biocompatibility

These TDDSs, mainly, when fabricated with synthesis materials, nanoparticles, can give rise to immune responses which may lead to inflammation, shrunken circulation time, or clearance by the immune system. The immune system of the body recognizes the carrier as a foreign entity and removes it before it reaches the tumor site. This particular immunogenicity could act as a hurdle for delivery and hence gets the carrier surface modified for better biocompatibility (such as coatings with polyethylene glycol- PEGylation).

8. Regulatory and Clinical Approval

The approval for TDDS comes with thorough preclinical and clinical investigations regarding their safety and efficacy, along with their manufacturing processes. Regulatory branches such as the FDA and EMA will require an exhaustive amount of data just to prove that TDDS reach their desired therapeutic outcomes without inflicting much harm to patients. Such innovative and specific applications of TDDS may involve the use of new materials or combinations of drugs, and can hence complicate and prolong the path to regulatory approval.[44,45]

9. High Cost of Development

The enormous cost of research, formulation, and clinical trials-a stupendous investment in these functions-is one of the notable demerits at the moment in the development of TDDS. Multi-functional delivery system design is complicated, coupled with big-scale manufacturing costs, translating inherently to greater costs than traditional drug therapies. This situation would limit access to highly advanced therapies, especially in settings with limited resources. As the technology progresses, a very relevant issue would be to find means through which costs may be reduced but efficacy is retained for TDDS to be adopted more widely at some future point in time in oncology.

10. Pharmacokinetics and Biodistribution

The pharmacokinetics of TDDS, which involves distribution, metabolism, and elimination, may become unpredictable; the performance characteristics of this carrier system in the body, for instance, clearance rate and half-life, may really have a big impact on a therapeutic outcome. For instance, some carrier systems may retain themselves into non-target organs (like liver or spleen), which leads to decrease in tumor drug concentration. Favorable biodistribution with controlled release of the drug would be one of the important challenges for the optimization of TDDS.[46,47,48]

FUTURE DIRECTIONS IN TARGETED DRUG DELIVERY

The advancements in future medicine focusing on oncology targeted drug delivery (TDD) include those associated with nanotechnology, personalized medicine, and biomarker-discovery research. One direction would be the design and synthesis of multi-functional nanoparticles capable of carrying more than one therapeutic agent-such as a pipeline chemotherapy drug, one for gene therapy, and another for immunotherapy-for centralized delivery to the lesions of interest. Such carrier sets can also be engineered to enhance drug bioavailability, increase penetration to the tumor site, or improve selectivity toxicity profiles. Another very exciting area is the introduction of biomarker-driven precision medicine, such that TDD systems are designed to target the inherited genetic or molecular features of individual tumors. Thus, the treatment would be more efficient since its based on the unique profile of each patient's cancer.

The promising future trend is in stimuli-responsive systems where drug release is triggered under conditions existing in the tumor microenvironment, like tumor pH, temperature, or enzyme activity. These systems would ensure that the release of drug occurs only when needed, increasing efficacy and diminishing side effects. Combining immunotherapy and targeted delivery will provide a completely new opportunity for the enhancement of the immune response of the body against cancer. These services will definitely evolve into improving efficacy, safety, and affordability in cancer therapy, thus improving the state of patients.[49,50]

CONCLUSION

Targeted drug delivery systems revolutionized the oncology landscape since they provide more precise and effective treatment of cancer. Targeted drug delivery systems offer the promise of improved efficacy of existing therapeutics-for example, chemotherapy, immunotherapy, and gene therapies-through the selective delivery of therapeutic agents to the tumor cells themselves while keeping systemic toxicity to a minimum. With in-progress, new biomarker-targeted TDDS, developing stimulus-activated TDDS, and novel combinatorial therapies, the potential for achieving individualized patient treatment has expanded. There are many challenges with these systems arising primarily from a failure to penetrate the tumors and controlled systemic release of the drug. Nevertheless, developments in nanotechnology and biomarker discoveries still hold out great promise of future solutions to these challenges. The future of cancer therapy is, in fact, TDDS, which is destined to improve clinical outcome in treatment and is expected

to lay the foundation for targeted, less toxic and personalized therapeutic modalities. As research progresses on this front, TDDS will take its rightful place in the future of modern oncology, establishing the pathway for better individual treatments and ultimately improving the quality of life and survival of patients.

REFERENCES

1. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Mol Cancer Res, 2023 Nov 1; 21(11): 1142-1147.
2. Gatenby RA, Brown J. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta Rev Cancer, 2017; 1867: 162–6.
3. Huxley J. Cancer biology: comparative and genetic. Biol Rev, 1956; 31: 474–514.
4. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci), 2018 Sep-Dec; 6(3-4): 79-100.
5. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Pérez de la Lastra JM. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis., 2022 Mar 18; 10(4): 1367-1401.
6. Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Mol Cell Proteomics, 2024 Mar; 23(3): 100737.
7. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted Drug Delivery - From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. J Multidiscip Healthc, 2021 Jul 5; 14: 1711-1724.
8. Thakur A, Roy A, Chatterjee S, Chakraborty P, Bhattacharya K, Mahata PP. Recent trends in targeted drug delivery. *SMGroup*, 2015.
9. Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, Fan Z, Li J. Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics, 2023 Aug 29; 15(9): 2233.
10. Pushpalatha R., Selvamuthukumar S., Kilimozhi D. Nanocarrier Mediated Combination Drug Delivery for Chemotherapy—A Review. J. Drug Deliv. Sci. Technol, 2017; 39: 362–371.
11. Prabahar K, Alanazi Z, Qushawy M. Targeted Drug Delivery System: Advantages, Carriers and Strategies. Indian J of Pharmaceutical Education and Research, 2021; 55(2): 346-53.
12. Mishra N, Pant P, Porwal A, Jaiswal J, Aquib M. Targeted drug delivery: A review. Am J Pharm Tech Res., 2016; 6: 2249-3387.
13. Rani K, Paliwal S. A review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics. Sch J App Med Sci., 2014; 2(1C): 328-31.
14. Manish G, Vimukta S. Targeted drug delivery system: A review. Res J Chem Sci., 2011; 1(2): 135-8.
15. Agnihotri J, Saraf S, Khale A. Targeting: New potential carriers for targeted drug delivery system. Int J Pharm Sci Rev Res., 2011; 8(2): 117-23.
16. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol., 2010 Oct; 27(7): 286-98.
17. Mills JK, Needham D. Targeted drug delivery. Expert Opin Ther Pat., 1999; 9(11): 1499-513.

18. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev., 2016 Apr 1; 99(Pt A): 28-51.
19. Nikolova MP, Kumar EM, Chavali MS. Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment. Pharmaceutics, 2022 Oct 15; 14(10): 2195.
20. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules, 2020 May 8; 25(9): 2193.
21. Hong L, Li W, Li Y, Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces. RSC Adv., 2023 Jul 17; 13(31): 21365-21382.
22. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Controlled Release, 2011; 153(3): 198.
23. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 2022 Feb 17; 27(4): 1372.
24. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on Responses in Biological Systems. Polymers (Basel), 2023 Mar 23; 15(7): 1596.
25. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep., 2015 Jun 12; 35(4): e00225.
26. Begines B, Ortiz T, Pérez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, Alcudia A. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials (Basel), 2020 Jul 19; 10(7): 1403.
27. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci., 2014 Jul; 6(3): 139-50.
28. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res., 2006 Sep; 4(3): 218-27.
29. He H, Pham-Huy LA, Dramou P, Xiao D, Zuo P, Pham-Huy C. Carbon nanotubes: applications in pharmacy and medicine. Biomed Res Int., 2013; 2013: 578290.
30. He X, Li J, An S, Jiang C. pH-sensitive drug-delivery systems for tumor targeting. Ther Deliv., 2013 Dec; 4(12): 1499-510.
31. Koh HB, Kim HJ, Kang SW, Yoo TH. Exosome-Based Drug Delivery: Translation from Bench to Clinic. Pharmaceutics, 2023 Jul 29; 15(8): 2042.
32. Naseri N, Valizadeh H, Zakeri-Milani P. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull, 2015 Sep; 5(3): 305-13.
33. Agnihotri J, Saraf S, Khale A. Targeting: New potential carriers for targeted drug delivery system. Int J Pharm Sci Rev Res, 2011; 8(2): 117-23.
34. Bhargav E, Madhuri N, Ramesh K, Ravi V. Targeted drug delivery: A review. WJPPS, 2013; 3(1): 150-9.
35. Mali S. Nanorobots: Changing face of healthcare system. Austin J Biomed Eng, 2014; 1(3): 3.
36. Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2017 Sep; 9(5): 10.1002/wnan.1450
37. Xue X, Liang XJ. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer, 2012 Feb; 31(2): 100-9.

38. Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, Rovira R, Ruiz R, Martín-Lorente C, Corchero JL, Céspedes MV. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules, 2022 Jun 4; 12(6): 784.
39. Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, Fang Q, Yu J, Chen P, Wu S, Zheng Z, He Y. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med, 2021 Aug; 9(16): 1351.
40. Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, Sausville EL, Lukow DA, Liu L, Chait AR, Galluzzo ZC, Tucker C, Sheltzer JM. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med, 2019 Sep 11; 11(509): eaaw8412.
41. Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci, 2022 Oct 17; 29(1): 83.
42. Nabil G, Bhise K, Sau S, Atef M, El-Banna HA, Iyer AK. Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation. Drug Discov Today, 2019 Feb; 24(2): 462-491.
43. Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials, 2009; 30(4): 649-57.
44. Cherukuri S, Batchu UR, Mandava K, Cherukuri V, Ganapuram KR. Formulation and evaluation of transdermal drug delivery of topiramate. Int J Pharm Investing, 2017 Jan-Mar; 7(1): 10-17.
45. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. Int J Pharm Investing, 2012 Jan; 2(1): 2-11.
46. Kim E, Yang J, Park S, Shin K. Factors Affecting Success of New Drug Clinical Trials. Ther Innov Regul Sci., 2023 Jul; 57(4): 737-750.
47. Glassman PM, Muzykantov VR. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. J Pharmacol Exp Ther, 2019 Sep; 370(3): 570-580.
48. Rosenblum, D., Joshi, N., Tao, W. *et al.* Progress and challenges towards targeted delivery of cancer therapeutics. *Nat Commun*, 2018; 9: 1410.
49. Abballe L., Spinello Z., Antonacci C., Coppola L., Miele E., Catanzaro G., Miele E. Nanoparticles for Drug and Gene Delivery in Pediatric Brain Tumors' Cancer Stem Cells: Current Knowledge and Future Perspectives. Pharmaceutics, 2023; 15: 505.
50. Hristova-Panusheva K, Xenodochidis C, Georgieva M, Krasteva N. Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. *Pharmaceuticals*, 2024; 17(6): 677.